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We have previously shown that tamoxifenþepigallocatechin gallate (EGCG) is synergistically cytotoxic towards oestrogen receptor
(ER)-negative breast cancer cells. To determine if this response would correlate with significant tumour suppression in vivo, athymic
nude female mice were implanted with MDA-MB-231 cells and treated with tamoxifen, EGCG, EGCGþtamoxifen, or vehicle
control for 10 weeks. Tumour volume in EGCG- (25mgkg
 1)þtamoxifen (75mgkg
 1)-treated mice decreased by 71% as
compared with vehicle control (Po0.05), whereas tumour weight was decreased by 80% compared with control (Po0.01).
Epigallocatechin gallate treatment did not alter ER protein expression in MDA-MB-231 cells and thus was not a mechanism for the
observed tumour suppression. However, western blotting of tumour extracts demonstrated that epidermal growth factor receptor
(EGFR; 85% lower than control), pEGFR (78% lower than control), mammalian target of rapamycin (mTOR; 78% lower than control),
and CYP1B1 (75% lower than control) were significantly lower after the combination treatment as compared with all other
treatments. Nuclear factor-kB (NF-kB), b-Raf, p-MEK, S6K, 4EBP1, Akt, vascular EGFR-1 (VEGFR-1) and VEGF expressions were
decreased in control but not in the individual treatments, whereas MEK, phospholipase D 1/2, TGFa, and ERK expressions were not
changed after any treatment. The results demonstrate that tamoxifen at realistic doses (75mgkg
 1) can suppress the growth of ER-
negative breast cancer when combined with EGCG. In addition, the dominant mechanism for tumour suppression is the concomitant
decrease in tumour protein expressions of mTOR and the EGFR.
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Tamoxifen has been extensively used in the treatment of oestrogen
receptor (ER)-positive breast cancer and was recently approved for
chemoprevention in high-risk women (Fisher et al, 1998, 2005). In
ER-positive breast cancer, tamoxifen acts as an SERM, as it
antagonises the binding of estradiol to the ER. However, tamoxifen
is not a highly selective drug and it elicits pro-apoptotic effects in
ER-negative breast cancer cells by the modulation of various cell
signalling proteins in an ER-independent manner (Fattman et al,
1998; Ferlini et al, 1999; Mandlekar et al, 2000). However, these
effects have generally been reported following relatively high
concentrations of tamoxifen. An appealing strategy would be to
use tamoxifen in combination with other agents to enhance its
action in ER-negative breast cancer. This concept has been shown
by combining docetaxel, genistein, black cohosh, and palm oil
tocotrienols (Ferlini et al, 1997; Guthrie et al, 1997; Tanos et al,
2002; Bollig et al, 2005; Al-Akoum et al, 2007) with tamoxifen,
which elicited cytotoxicity, apoptosis, and G1 arrest in various ER-
negative breast cancer cell lines. Recently, this has been shown in
both MDA-MB-231 cells and a xenograft model by combining
tamoxifen with OSU-03012, a phosphoinositide-dependent protein
kinase-1/Akt inhibitor (Weng et al, 2008). Our laboratory has also
used ER-negative breast cancer cells to demonstrate that a
combination of epigallocatechin gallate (EGCG) and tamoxifen
elicits synergistic cytotoxicity (Chisholm et al, 2004). We further
demonstrated that EGCGþtamoxifen elicits an earlier and
enhanced apoptotic response in MDA-MB-231 cells (Stuart et al,
2007), and this correlated with a decrease in protein expression of
the active form of the epidermal growth factor receptor (EGFR)
after combination treatment (Stuart and Rosengren, 2007).
The EGFR is a clinically significant target for ER-negative breast
cancer, as it is overexpressed in ER-negative breast cancer cells
(Roos et al, 1986) as well as in patients with ER-negative breast
cancer (Biswas et al, 2004). Furthermore, it is involved in cell
proliferation, apoptosis, angiogenesis, tumour invasiveness, and
distant metastases (Grandis and Sok, 2004). The EGFR exerts its
effects on cellular function through the activation of numerous
downstream signalling pathways, including the Raf–MEK–ERK
mitogen-activated protein kinase pathway and the PI3K–Akt
pathway (Dutta and Maity, 2007). The stimulation of the
Raf–MEK–ERK cascade leads to the activation of numerous
transcription factors that are important for cell proliferation and
survival (Brott et al, 1993). Epidermal growth factor receptor
signalling through the PI3K–Akt pathway results in the activation
of the transcription factor nuclear factor-kB (NF-kB) (constitu-
tively active in ERa  breast cancers) and mammalian target of
rapamycin (mTOR), an important regulator of protein synthesis
(Averous and Proud, 2006). Recently, the importance of the dual
suppression of both EGFR and mTOR expressions was shown
when the proliferation of breast cancer was synergistically reduced
after the inhibition of both EGFR and mTOR expressions (Buck
et al, 2006).
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suppression potential of the combination of EGCGþtamoxifen in
a xenograft model of ER-negative breast cancer. On the basis of
our previous in vitro studies in MDA-MB-231 cells, we postulated
that the inhibition of both EGFR and mTOR expressions would be
important mechanisms for tumour suppression after combination
treatment. Therefore, we measured EGFR and its major down-
stream targets in tumours to demonstrate drug-mediated effects on
critical cell signalling pathways from treated mice. We also
examined tumour protein expression of CYP1B1, because this
protein provides a new target for the suppression of tumour
growth, as it is overexpressed in many human cancers, including
breast cancer (Murray et al, 1997).
MATERIALS AND METHODS
Chemicals and reagents
Epigallocatechin gallate (99% purity) was purchased from the
Cayman Chemical Company (Ann Arbor, MI, USA). MDA-MB-231
human breast cancer cells were purchased from ATCC (Manassas,
VA, USA). Matrigel and the primary antibodies Akt, pAkt, EGFR,
pEGFR and CYP1B1 were purchased from BD Biosciences
(Auckland, New Zealand). Minimum essential medium, potassium
chloride, NaHCO3, NaCl, trizma hydrochloride, Triton X-100,
trypsin, and trypan blue were purchased from Sigma Chemical Co.
(St Louis, MO, USA). Acetic acid, disodium hydrogen ortho-
phosphate anhydrous, EDTA, DMSO, potassium dihydrogen
orthophosphate, and sodium citrate were purchased from BDH
Laboratory supplies (Poole, UK). Primary antibodies NF-kB, bRaf,
TGFa, 4EBP1, p4EBP1, vascular endothelial growth factor receptor
(VEGF), VEGFR-1, mTOR, PLD1, PLD2, S6K, pS6K, MEK, pMEK,
ERK, pERK, ERa, and ERb were purchased from Abcam
(Cambridge, MA, USA). Foetal bovine serum was purchased from
Life Technologies Ltd. (Auckland, New Zealand). All other
chemicals were the highest purity commercially available.
Cell culture
MDA-MB-231 and MCF-7 cells were maintained in minimum
essential medium supplemented with 10% foetal bovine serum, 1%
antibiotic/antimitotic solution, and 0.2% NaHCO3. Cells were
cultured in 75cm
2 flasks and incubated in 5% CO2/95% humidified
air at 371C.
Animals and treatment
Female CD1 athymic nude mice (5- to 6-week old) were purchased
from Hercus Taieri Resource Unit (Dunedin, New Zealand). They
had free access to sterilised standard Reliance Rodent Diet
(Dunedin, New Zealand) and water, and were housed four mice
per cage and maintained at 21–241C with a 12-h light/dark cycle in
a specifically designed pathogen-free isolation facility and allowed
to acclimatise for 1 week before experimentation. The University
of Otago Animal Ethics Committee approved all procedures. Mice
were inoculated into the right flank with ER-negative cells (MDA-
MB-231, 2 10
6/50ml matrigel), which were left to form palpable
tumours. Tumour volume was measured weekly with electronic
calipers (LWH). When the tumour volume reached 100mm
3, mice
(10 per group) were randomly assigned to the various treatment
groups. Mice were then treated daily with tamoxifen (50 or
75mgkg
 1), EGCG (25mgkg
 1), EGCGþtamoxifen, or a vehicle
control for each drug (5mlkg
 1) for 10 weeks. Dosing solutions
were prepared fresh each day. Tamoxifen was given through oral
gavage, whereas EGCG was given intraperitoneally. On the account
of extensive first-pass metabolism (Li et al, 2001), EGCG is often
administered parentally (Liao et al, 1995; Landis-Piwowar et al,
2007; Somers-Edgar et al, 2008). In addition, the dose of EGCG
(25mgkg
 1, i.p.) was based on our previous study, which
demonstrated that this dose was non-toxic and elicited a modest
decrease in MDA-MB-231 tumour growth (Somers-Edgar et al,
2008). This dose is also twofold lower than that recently
used in other ER-negative xenograft experiments with EGCG
(Landis-Piwowar et al, 2007; Thangapazham et al, 2007). On the
basis of our in vitro experiments with EGCGþtamoxifen, we
wanted to use a very low dose of tamoxifen. Therefore, we chose a
dose of tamoxifen that was at least 10-fold lower than that has
typically been used in other xenograft studies.
Assessment of animal health
Food consumption and body weight were monitored daily
throughout the treatment period. Mice were euthanised by CO2
inhalation 24h after the last dose and necropsies were then
performed. Blood was collected through the inferior vena cava
and placed on ice, whereas major organs, as well as tumours, were
excised and weighed. Organ weights are expressed as a percentage of
body weight. Plasma was separated and used to determine the
presence of hepatotoxicity via the plasma marker alanine amino-
transferase activity using a commercially available kit (Medica
Pacifica, Auckland, New Zealand). Results are expressed as IUl
 1.
Preparation of whole cell lysates
MDA-MB-231 and MCF-7 cells were plated (200000 cells per well)
in six-well plates and treated for 24h with EGCG (100mM)o r
estradiol (100nM). Cells were harvested using a cell scraper, washed,
and incubated in RIPA buffer (50mM Tris base, 1% NP-40, 0.25%
sodium deoxycolate, 100mM sodium chloride, 1mM EDTA, and
complete protease inhibitor cocktail tablets; Roche, Mannheim,
Germany), incubated on ice for 15min, and centrifuged at
13000r.p.m. for 10min at 41C. The supernatant was collected and
the protein concentration was determined using the BCA assay.
Western blotting of proteins from cell lysates or tumour
extracts
Protein extraction from tumour tissue was performed as described
(Somers-Edgar et al, 2008). The extracts or cell lysates were
fractioned by SDS–PAGE, electrotransferred to nitrocellulose
membranes, blotted with each antibody, and detected by amplified
colour reagent (Bio-Rad, Auckland, New Zealand). b-Actin was
used as a loading control, and the density of each band was
normalised to the b-actin control. For clarity in the figures,
densitometry is shown only for proteins that were modulated by
drug treatment.
Immunohistochemistry of tumour sections
Tumours were embedded in OCT compound and then sectioned
(5mm), fixed in acetone, and air-dried overnight. Sections were
then washed twice in Tween 20–PBS, incubated with normal
serum for 30min at room temperature, and then incubated
overnight with primary CYP1B1 or VEGFR-1 antibody. Slides were
then rinsed and peroxidase blocked using hydrogen peroxide (3%)
before incubation with the appropriate secondary antibody for
30min at room temperature in a humidified chamber. The sections
were then incubated with ExtrAvidin (Bio-Rad, Auckland, New
Zealand) (1:20) for 30min at room temperature in a humidified
chamber before development with 3,30-diaminobenzidine tetrahy-
drochloride as the chromogen and counterstaining with Mayer’s
haematoxylin. Once slides were dehydrated, DPX mounting
medium and coverslips were applied. The sections were analysed
from tumours obtained from each mouse and a representative
slide is shown in the results section.
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For all parameters where the variances were significantly different
between control and treated mice (namely, tumour volume and
tumour weight), the data were log-transformed before statistical
analysis was performed. Tumour growth experiments were
analysed using a repeated measures two-way ANOVA coupled
with a Student–Newman–Keuls post hoc test, in which Po0.05
was the minimum requirement for a statistically significant
difference. Analyses that did not involve time (i.e., tumour weight
and protein expression) were analysed using an one-way ANOVA
coupled with a Student–Newman–Keuls post hoc test, in which
Po0.05 was the minimum requirement for a statistically
significant difference.
RESULTS
The combination of EGCG and tamoxifen suppresses
tumour growth in vivo
When EGCG (25mgkg
 1) was combined with tamoxifen
(50mgkg
 1), the growth rate of the tumours in the combination
treated mice lagged behind the other treatments, but an overall
significant decrease in tumour growth was not observed
(Figure 1A). A significant decrease in tumour growth was observed
when the dose of tamoxifen in combination with EGCG was
increased to 75mgkg
 1. Specifically, after 6 weeks of treatment, the
growth curve from the combination treated mice diverged from
other treatments (Figure 1B). After 10 weeks of treatment, the
combination treated mice had a tumour volume that was 71.3%
smaller than both the vehicle- and tamoxifen-treated mice
(Po0.05). Tumour weight was also decreased significantly after
combination treatment (tumour weights of 0.45±0.08, 0.45±0.14,
0.29±0.4 and 0.09±0.2g for vehicle, tamoxifen, EGCG and
EGCGþtamoxifen, respectively) (Figure 1C). Importantly, the
drug treatments were well tolerated and non-toxic to the mice, as
weight gain and all other physiological parameters (i.e., liver,
kidney, spleen and uterine weight) were in the normal range (data
not shown) and no hepatotoxicity was observed as alanine
aminotransferase activity was not elevated following any of the
drug treatments (values ranged between 23 and 27IUl
 1).
EGCG does not reverse the ER status of MDA-MB-231
breast cancer cells
As EGCG has upregulated ERa expression in cell lines with a low
ERa expression (Belguise et al, 2007), it was necessary to
determine whether the tumour suppression could be due to an
EGCG-mediated change in the protein expression of the ER in
MDA-MB-231 cells. Therefore, MDA-MB-231 cells were treated
with EGCG (100mM) or estradiol (100nM) for 24h, and MCF-7 cells
were treated with estradiol (100nM) as a control. The results
demonstrated that estradiol increased the protein expression of
both ERa and ERb in MCF-7 cells, whereas neither EGCG nor
estradiol induced the protein expression of the ER in MDA-MB-
231 cells (Figure 2).
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Figure 1 Tumour growth after the treatment with EGCG and tamoxifen. Female athymic nude mice were implanted with MDA-MB-231 cells (2 10
6)
and treated for 70 days. (A) Tumour volume during the treatment with vehicle (5mlkg
 1), EGCG (25mgkg
 1, i.p.), tamoxifen (50mgkg
 1, p.o.), or
EGCGþtamoxifen. (B) The tumour volume during treatment with vehicle (5mlkg
 1), EGCG (25mgkg
 1, i.p.), tamoxifen (75mgkg
 1, p.o.),
or EGCGþtamoxifen. (C) Tumour weight after 70 days of treatment with EGCG (25mgkg
 1, i.p.) and tamoxifen (75mgkg
 1, p.o.). Symbols and bars
represent the mean±s.e.m. from 10 mice per group. *Combination treatment significantly different from vehicle control (Po0.05). **Combination
treatment significantly different from all other groups (Po0.05).
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Figure 2 Protein expressions of ERa and ERb in MCF-7 and MDA-MB-
231 cells. Cells were treated with 100nM of estradiol (E2) or with 100mM of
EGCG for 24h. The blots shown are representative of three independent
experiments performed in duplicate.
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and mTOR in vivo
As we have previously shown that EGCGþ4-OHT produces an
earlier and greater apoptotic response (Stuart et al, 2007) and
elicits a greater inhibition of pEGFR in MDA-MB-231 cells (Stuart
and Rosengren, 2007), the role of the EGFR and other downstream
cell signalling proteins were determined in tumour extracts. The
results showed that the protein expression of EGFR was
significantly decreased in tumours from combination-treated mice
as compared with all other treatments (relative density of EGFR in
the EGCGþtamoxifen group was decreased by 85.3±3.33,
76.0±5.5 and 71.2±6.6% as compared with control, EGCG, and
tamoxifen, respectively, Po0.001) (Figure 3A and B). A similar
trend was also observed for the active form of EGFR pEGFR
(relative density of pEGFR in the EGCGþtamoxifen group was
decreased by 78.4±5.3, 71.2±7.0 and 61.0±9.6% as compared
with control, tamoxifen, and EGCG, respectively, Po0.001) (Figure
3A and B). However, TGFa, a regulator of EGFR signalling, was not
changed following any of the treatments (Figure 3A). Given that
the combination of EGCGþtamoxifen significantly reduced levels
of both EGFR and pEGFR, downstream targets of this receptor
were examined. As the EGFR signals predominantly through the
mitogen-activated protein kinase cascade and the PI3K–Akt
pathways, components of these pathways were investigated.
Protein expression of the mitogen-activated protein kinase cascade
members MEK, ERK, and pERK were unchanged following any of
the treatments (Figure 3A). However, combination treatment
caused tumour protein levels of the ERK regulator pMEK to
decrease by 76.6±5.3% as compared with vehicle control
(Po0.05) (Figure 3A and B). Other downstream targets mea-
sured (Akt, NF-kB, and b-Raf) in tumours from combination-
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Figure 3 Tumour protein expression levels of EGFR, Akt, NF-kB, b-Raf, ERK and MEK after treatment with EGCG and tamoxifen. Mice were treated with
vehicle (5mlkg
 1), EGCG (25mgkg
 1, i.p.), tamoxifen (75mgkg
 1, p.o.), or EGCGþtamoxifen for 70 days. (A) Representative western blots of the various
proteins from each individual mouse. (B) The results of scanning densitometry of western blots. For clarity, densitometry is shown only for proteins that
were modulated by drug treatment. Bars represent the mean±s.e.m. from 10 mice per group. *Significantly different from vehicle control (Po0.05).
**Significantly different from vehicle and EGCG (Po0.01). ***Significantly different from all other treatments (Po0001).
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p-Akt and NF-kB were also decreased in control and EGCG
(Figure 3A and B).
As mTOR is a major regulator of protein translation and other
processes important in cell proliferation, this protein as well as its
targets, S6K and 4EBP1 were also examined in tumour extracts.
The results demonstrated that protein expression of mTOR and
S6K were significantly decreased in tumours from combination
treatment mice as compared with all other treatment groups
(relative density of mTOR was decreased by 78.0±6.9, 78.4±6.8
and 80.0±6.3% as compared with control, tamoxifen, and EGCG,
respectively, Po0.001) (Figure 4A and B). However, pS6K was not
changed following any of the treatments, whereas both 4EBP1 and
p4EBP1 were decreased in control but not in the individual
treatments (Figure 4A and B). Phospholipase D (PLD) 1 and 2
represent an alternate upstream regulator of mTOR. However, the
protein expression of these isoforms was not altered by any of the
treatments (Figure 4A).
The combination of EGCG and tamoxifen regulates VEGF,
VEGFR-1, and CYP1B1 in vivo
The tumour marker CYP1B1 was also decreased by 71.5% in
tumour tissue from combination-treated mice as compared with
vehicle control as shown by western blotting and immunohisto-
chemistry (Figure 5A–C). This protein was also decreased as
compared with each single drug treatment (relative intensities of
1.98±0.42, 4.47±0.48, and 5.88±1.69 for EGCGþtamoxifen,
tamoxifen, and EGCG, respectively, Po0.05). To gain insight
into the role of angiogenesis in the growing tumour, VEGF,
an important regulator of angiogenesis (Sledge, 2002), which also
aids in breast cancer cell survival (Wu et al, 2006), was
examined in tumour extracts. All treatments decreased both VEGF
and its receptor VEGFR-1 approximately 50% from control as
shown by both western blotting and immunohistochemistry
(Figure 5A–C), but this effect was not enhanced after combination
treatment.
DISCUSSION
We have shown that the combination of tamoxifen (75mgkg
 1,
p.o.) and EGCG (25mgkg, i.p.) inhibits the growth of MDA-MB-
231 xenografts and that this effect is superior to that elicited by
either individual treatment. Another study has shown that the
combination of green tea extract (2.5g/l) and tamoxifen (20mg
pellet) is better than either drug alone at suppressing the growth of
MCF-7 xenografts, and this correlated with increased levels of
apoptosis and a suppression of angiogenesis in tumour tissue
(Sartippour et al, 2006). However, this drug combination has not
previously been examined in an in vivo model of ER-negative
breast cancer.
Our results demonstrated that tamoxifen on its own was not
effective at suppressing ER-negative tumour growth, whereas
EGCG had a modest effect on tumour growth, but the combination
of the two drugs showed marked tumour suppression.
Other studies have also shown that EGCG or green tea extract
has a modest inhibitory effect on ER-negative tumour growth
(Landis-Piwowar et al, 2007; Thangapazham et al, 2007;
Somers-Edgar et al, 2008). For example, EGCG (50mgkg
 1, s.c.)
was minimally effective at reducing tumour growth in a MDA-MB-
231 xenograft model, but acetylating EGCG and thus turning it into
a pro-drug enhanced its efficacy (Landis-Piwowar et al, 2007). In a
similar xenograft model, the efficacy of EGCG was increased by the
addition of curcumin (Somers-Edgar et al, 2008). However, the
overall tumour volume was only decreased by 49% as compared
with control after EGCGþcurcumin treatment, indicating that
EGCGþtamoxifen is a more effective combination therapy as
tumour volume was decreased by 71% as compared with control.
Another recent study has shown that ER-negative breast cancer
cells can be sensitised to the effects of tamoxifen by using a PDK-1/
Akt inhibitor (Weng et al, 2008). In this study, tamoxifen
(60mgkg
 1) was unable to suppress the growth of MDA-MB-231
xenografts, but the addition of OUS-03012 (100mgkg
 1) showed
significant tumour suppression (decreased 50% in control). This
result supports the use of tamoxifen in combination therapies for
ER-negative breast cancer. However, our combination with EGCG
produced a greater level of tumour suppression at a much lower
dose of tamoxifen (75mgkg
 1).
The mechanism responsible for the enhanced tumour
suppression and apoptosis (Stuart et al, 2007) elicited by
EGCGþtamoxifen does not involve EGCG-mediated changes in
the ER status of MDA-MB-231 cells. Furthermore, when the ER is
present, tamoxifen acts to antagonise the effects of estradiol, and
as our model does not involve the use of estradiol pellets, there
is no ER-mediated response to antagonise. Instead, the mechanism
is most likely to be initiated by the modulation of EGFR activity.
Our results demonstrate that both protein levels of EGFR and
its active phosphorylated form are significantly reduced by
EGCGþtamoxifen treatment. Although there was no further
reduction in the active form of EGFR after combination treatment,
the similar decrease in both the unphosphorylated and
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Figure 4 Tumour protein expression levels of mTOR, S6K and 4EBP1
after treatment with EGCG and tamoxifen. Mice were treated with vehicle
(5mlkg
 1), EGCG (25mgkg
 1, i.p.), tamoxifen (75mgkg
 1, p.o.), or
EGCGþtamoxifen for 70 days. (A) Representative western blots of the
various proteins from each individual mouse. (B) The results of scanning
densitometry of western blots. For clarity, densitometry is shown only for
proteins that were modulated by drug treatment. Bars represent the
mean±s.e.m. from 10 mice per group. *Significantly different from vehicle
control (Po0.05). **Significantly different from vehicle and EGCG
(Po0.01). ***Significantly different to all other treatments (Po0001).
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pathway as a whole was reduced by approximately 78% by the
combination treatment. Combination treatment also caused a
similar reduction in the protein expression of mTOR. The
inhibition of mTOR is of particular significance, as this is a key
regulator of protein synthesis within the cell. Furthermore, the
growth of renal cell carcinoma (Gemmill et al, 2005), glioblastoma
multiforme (Goudar et al, 2005), as well as non-small-cell lung
cancer, pancreatic, colon, and breast (Buck et al, 2006) cancers
were synergistically reduced when EGFR inhibitors were combined
with the mTOR inhibitor rapamycin. The in vitro results correlated
with synergistic tumour suppression in a xenograft model of non-
small-cell lung cancer. Interestingly, the results showed neither of
the individual drugs significantly suppressed tumour growth, but
showed pronounced reduction after combination treatment. Our
results are very similar, in that pronounced reduction in tumour
growth only occurred after EGCGþtamoxifen. As a similar
(B80%) and significant reduction of EGFR and mTOR occurred
after combination therapy, it is most likely that this dual
suppression is a key mechanistic component of the observed
tumour suppression. Furthermore, the decreased expression of
mTOR is not likely to be regulated further upstream through
PLD1/2, as levels of PLD1 and PLD2 were not altered by any drug
treatments. However, the combined inhibition of EGFR, Akt, and
mTOR after EGCGþtamoxifen treatment provides a powerful
suppression of tumour growth.
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Figure 5 Tumour protein expression levels of VEGF, VEGFR-1, and CYP1B1 after treatment with EGCG and tamoxifen. Mice were treated with vehicle
(5mlkg
 1), EGCG (25mgkg
 1, i.p.), tamoxifen (75mgkg
 1, p.o.), or EGCGþtamoxifen for 70 days. (A) Representative western blots of the various
proteins from each individual mouse. (B) The results of scanning densitometry of western blots. For clarity, densitometry is shown only for proteins that
were modulated by drug treatment. Bars represent the mean±s.e.m. from 10 mice per group. (C) Representative immunohistochemistry of CYP1B1 and
VEGFR-1 from tumour sections of treated mice. *Significantly different from vehicle control (Po0.05). **Significantly different from vehicle and tamoxifen
(Po0.01). ***Significantly different from all other treatments (Po0001).
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that it decreases angiogenesis (Cao and Cao, 1999; Sartippour et al,
2001, 2002). Our results support this, as tumour-derived VEGF was
decreased after EGCG treatment. Therefore, the inhibition of VEGF
after combination treatment appears to be mediated by EGCG, and
thus the inhibition of tumour-derived VEGF is not a mechanism
for the combination treatment. However, VEGF and VEGFR-1
levels in the surrounding mouse stromal tissue would provide
additional information regarding the overall effect of the drug
treatment on angiogenesis.
Another important effect elicited by the drug combination is the
78% decrease in the protein expression of CYP1B1. CYP1B1 has
not been examined previously following the in vivo administration
of EGCG. However, this protein could be important in ER-negative
breast cancer, as the CYP1B1_1358_A4G polymorphism has been
significantly associated with ER-negatvie tumour status (Justen-
hoven et al, 2008). This genotype is known to encode higher
CYP1B1 activity and it is believed to contribute to low levels of the
ER in these tumours by a reduction in estradiol. As EGCG has been
shown to modulate CYP1B1 in MCF-7 cells (Guengerich et al,
2003) and antagonise AhR-mediated responses (Palermo et al,
2005), our results of decreased CYP1B1 protein expression after
combination treatment is not surprising. The role of CYP1B1 in
tumour suppression was also shown in a study where CYP1B1 null
mice were protected against DMBA-induced tumours as compared
with their wild-type counterparts (Buters et al, 1999). As CYP1B1
can inactivate the prostate cancer dug flutamide (Rochat et al,
2001) and is also induced in breast cancer cells after treatment with
docetaxel (Martinez et al, 2008), it may have an important function
in the development of resistance to chemotherapy. Overall,
CYP1B1 has a variety of functions in both the treatment and
development of breast cancer. Therefore, the 78% inhibition of
CYP1B1 elicited by EGCGþtamoxifen treatment is a critical
component of its mechanism of action.
In summary, we have demonstrated that the combination of
EGCGþtamoxifen significantly reduced ER-negative tumour
growth and that this was driven primarily by an enhanced effect
by the decreased protein expression of the EGFR, mTOR, and
CYP1B1. Overall, our findings suggest that EGCGþtamoxifen as an
antitumorigenic therapy in ER-negative breast cancer is promising
and thus this combination warrants further investigation.
ACKNOWLEDGEMENTS
We thank Martin J Le Nedelec for his technical assistance. This
work was funded by grants from the Breast Cancer Research Trust
and University of Otago Faculty of Medicine Bequest Funds.
University of Otago Postgraduate Scholarships were awarded to
MJS, ECS, TJS-E and ARM.
REFERENCES
Al-Akoum M, Dodin S, Akoum A (2007) Synergistic cytotoxic effects of
tamoxifen and black cohosh on MCF-7 and MDA-MB231 human breast
cancer cells: an in vitro study. Can J Physiol Pharmacol 85: 1153–1159
Averous J, Proud CG (2006) When translation meets transformation: the
mTOR story. Oncogene 25: 6423–6435
Belguise K, Guo S, Sonenshein GE (2007) Activation of FOXO3a by the
green tea polyphenol epigallocatehin-3-gallate induces estrogen receptor
a expression reversing invasive phenotype of breast cancer cells. Cancer
Res 67: 5763–5770
Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Perdee AB, Iglehart JD
(2004) NF-kB activation in human breast cancer specimens and its
role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:
10137–10142
Bollig A, Du Q-Q, Fan S-T, Yu B, Sarkar FH, Liao J (2005) Combination of
5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antago-
nists and cooperative effects on cytotoxicity in human mammary
carcinoma cells. Oncol Rep 14: 177–183
Brott BK, Alessandrini A, Largaespada DA, Copeland NG, Jenkins NA,
Crews CM, Erikson RL (1993) MEK2 is a kinase related to MEK 1
and is differentially expressed in murine tissues. Cell Growth Differ 4:
921–929
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK,
Gibson NW, Griffin G (2006) Rapamycin synergizes with the epidermal
growth factor receptor inhibitor erlotinib in non-small-cell lung,
pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676–2684
Buters JTM, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer
J, Ward JM, Jefcoate CR, Gonzalez FJ (1999) Cytochrome P450 CYP1B1
determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced
lymphomas. Proc Natl Acad Sci USA 96: 1977–1982
Cao Y, Cao R (1999) Angiogenesis inhibited by drinking tea. Nat Med
398: 381
Chisholm K, Bray BJ, Rosengren RJ (2004) Tamoxifen and epigallocatechin
gallate (EGCG) are synergistically cytotoxic to MDA-MB-231 human
breast cancer cells. Anticancer Drugs 15: 889–897
Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their
relevance to cancer therapy. Cancer Lett 254: 165–177
Fattman CL, An B, Sussman L, Dou QP (1998) p53-Independent depho-
sphorylation and cleavage of retinoblastoma protein during tamoxifen-
induced apoptosis in human breast cancer carcinoma cells. Cancer Lett
130: 103–113
Ferlini C, Scambia G, Distefano M, Filippinin P, Isola G, Riva A,
Bombardelli E, Fattorossi A, Benedetti Panici P, Mancuso S (1997)
Synergistic antiproliferative activity of tamoxifen and docetaxel on three
oestrogen receptor-negative cancer cell lines is mediated by the
induction of apoptosis. Br J Cancer 75: 884–891
Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G,
Fattorossi A, Isola G, Panici PB, Mancuso S (1999) Tamoxifen induced
oxidative stress and apoptosis in estrogen receptor-negative human
cancer cell lines. Br J Cancer 79: 257–263
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin
WM, Vogel V, Robidous A, Dimitrov N, Atkins J, Daly M, Wieand S,
Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of
breast cancer: report of the national Surgical Adjuvant Breast and Bowel
Project P-1 Study. J Natl Cancer Inst 90: 1371–1388
Fisher B, Costantino JP, Wickerham LD, Cecchini RS, Cronin WM,
Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG,
Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the
prevention of breast cancer: current status of the National Surgical
Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97:
1652–1662
Gemmill RM, Zhou M, Costa L, Bukowski RM, Drabki HA (2005)
Synergistic growth inhibition by Iressa and rapamycin is modulated by
VHL mutations in renal cell carcinoma. Br J Cancer 92: 2266–2277
Goudar RK, Shi Q, Hjelmelad MD, Keir ST, McLendon RE, Wikstrand CJ,
Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK,
Wang X, Bigner DD, Friedman HS, Rich JN (2005) Combination therapy
of inhibitors of epidermal growth factor receptor/vascular endothelial
growth factor receptor 2 (AE788) and the mammalian target of
rapamycin (RAD001) offers improved glioblastoma tumor inhibition.
Mol Cancer Ther 4: 101–112
Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor
receptor during the development of malignancy. Pharmacol Ther 102:
37–46
Guengerich FP, Chun Y-J, Kim D, Gillam EMJ, Shimada T (2003)
Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis
strategies. Mutat Res 523–524: 173–182
Guthrie N, Gapor A, Chambers AF, Carroll KK (1997) Inhibition of
proliferation of estrogen receptor negative MDA-MB-435 and positive
MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen,
alone and in combination. J Nutr 127: 544S–548S
EGCGþtamoxifen reduces ER  tumour growth
MJ Scandlyn et al
1062
British Journal of Cancer (2008) 99(7), 1056–1063 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sJustenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V,
Pesch B, Bru ¨ning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H
(2008) The CYP1B1_1358_GG genotype is associated with estrogen
receptor-negative breast cancer. Breast Cancer Res Treat 111: 171–177
Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP
(2007) A novel prodrug of the green tea polyphenol ( )-epigallocate-
chin-3-gallate as a potential anticancer agent. Cancer Res 67:
4303–4310
Li C, Meng X, Winnik B, Lee MJ, Lu H, Sheng S, Zhu N, Sheng S, Buckley B,
Yang CS (2001) Analysis of urinary metabolites of tea catechins by liquid
chromatography/electron ionization mass spectrometry. Chem Res
Toxicol 14: 702–707
Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA (1995) Growth
inhibition and regression of human prostate and breast tumors in
athymic mice by tea epigallocatechin gallate. Cancer Lett 96: 239–243
Mandlekar S, Yu R, Tan T-H, Kong A-NT (2000) Activation of caspase-3
and c-jun NH2-terminal kinase-1 signaling pathways in tamoxifen-
induced apoptosis of human breast cancer cells. Cancer Res 60:
5995–6000
Martinez VG, O’Connor R, Clynes M (2008) CYP1B1 expression is induced
by docetaxel: effect on cell viability and drug resistance. Br J Cancer 98:
564–570
Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD,
Melvin WT (1997) Tumor-specific expression of cytochrome P450
CYP1B1. Cancer Res 57: 3026–3031
Palermo CM, Westlake CA, Gasiewicz TA (2005) Epigallocatechin gallate
inhibits aryl hydrocarbon receptor gene transcription through an
indirect mechanism involving binding to a 90kDa heat shock protein.
Biochem Biophys Res Com 44: 5041–5052
Rochat BM, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human
CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific
drug inactivation? J Pharmacol Exp Ther 296: 537–541
Roos W, Fabbro D, Kung W, Costa SD, Eppenberger U (1986) Correlation
between hormone dependency and the regulation of epidermal growth
factor receptor by tumour promoters in human mammary carcinoma
cells. Proc Natl Acad Sci USA 83: 991–995
Sartippour MR, Heber D, Ma J, Lu Q, Go VL, Nguyen M (2001) Green
tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 40:
149–156
Sartippour MR, Pietras R, Marquez-Garban DC, Chen H-W, Heber D,
Henning SM, Sartippour G, Zhange L, Lu M, Weinberg O, Rao JY, Brooks
MN (2006) The combination of green tea and tamoxifen is effective
against breast cancer. Carcinogenesis 27: 2424–2433
Sartippour MR, Shao Z-M, Heber D, Beatyy P, Zhang L, Liu C, Ellis L,
Liu W, Go VL, Brooks MN (2002) Green tea inhibits vascular endothelial
growth factor (VEGF) induction in human breast cancer cells. J Nutr 132:
2307–2311
Sledge GW (2002) Vascular endothelial growth factor in breast cancer:
biologic and therapeutic aspects. Semin Oncol 29: 104–110
Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP,
Rosengren RJ (2008) The combination of epigallocatechin gallate and
curcumin suppresses ERa-breast cancer cell growth in vitro and in vivo.
Int J Cancer 122: 1966–1971
Stuart EC, Larsen L, Rosengren RJ (2007) Potential mechanisms for
the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallo-
catechin gallate in MDA-MB-231 cells. Int J Oncol 30: 1407–1412
Stuart EC, Rosengren RJ (2007) EGCG and 4-hydroxytamoxifen synergis-
tically induced cytotoxicity in MDA-MB-231 human breast cancer cells:
the role of apoptosis and signaling proteins. In American Association
for Cancer Research, pp 3282. Cadmus Professional Communications:
Los Angeles
Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T (2002) Synergistic
inhibitory effects of genistein and tamoxifen on human dysplastic and
malignant epithelial breast cell in vitro. Eur J Obst Gyn Repro Biol 102:
188–194
Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP,
Maheshwari RK (2007) Green tea polyphenols and its constituent
epigallocatechin gallate inhibits proliferation of human breast cancer
cells in vitro and in vivo. Cancer Lett 245: 232–241
Weng S-C, Kashida U, Kulp SK, Wang D, Brueggemeier RW, Shapiro C,
Chen C-S (2008) Sensitizing estrogen receptor-negative breast cancer
cells to tamoxifen with OSU-03012, a novel celecoxib-derived phophoi-
nositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer
Ther 7: 800–808
Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ (2006)
The vascular endothelial growth factor receptor (VEGFR-1) supports
growth and survival of human breast carcinoma. Int J Cancer 119:
1519–1529
EGCGþtamoxifen reduces ER  tumour growth
MJ Scandlyn et al
1063
British Journal of Cancer (2008) 99(7), 1056–1063 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s